Lymphocytic infiltration is one of the key factors dictating tumor responsiveness to immunotherapy.4 PCSK9-depleted tumors displayed significantly increased numbers of tumor-infiltrating lymphocytes, with intratumoral IFN-γ+ CTLs showing a higher raise in response to evolocumab than upon anti-PD1 antibody treatment. The gene discussed is IFNG; the disease is neoplasm.